Moderna, Inc. (0QF.F)
| Previous Close | 119.70 |
| Open | 115.42 |
| Bid | 113.50 x 0 |
| Ask | 114.00 x 0 |
| Day's Range | 114.86 - 116.96 |
| 52 Week Range | 59.44 - 132.06 |
| Volume | |
| Avg. Volume | 813 |
| Market Cap | 44.131B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated ...
- ACCESSWIRE
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza ...
- ACCESSWIRE
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise ...
